Tue, 29-Sep-2020
Thursday 06 Aug 2020 , 9:36 am

Teladoc Bets Big on Online Medicine with $18.5 Billion Livongo Deal

With the deal, Teladoc said it hopes to create an integrated system through which patients can see a doctor and manage their diseases virtually.
By SIN Bureau
Share at:

Remote medicine company Teladoc Health Inc has agreed to acquire chronic care provider Livongo Health Inc for $18.5 billion, seeking to expand its offerings amid a boom in virtual healthcare spurred by the coronavirus pandemic.

It is by far Teladoc’s largest acquisition after a series of smaller deals turned it into the biggest dedicated U.S. provider of mobile phone and internet-based healthcare services, following its initial public offering in 2015.

In those five years, Teladoc’s market value has increased tenfold to $17 billion based on growth prospects, given that the company has yet to turn a profit.

The coronavirus pandemic has supercharged the telemedicine market. McKinsey & Co has forecast that $250 billion of spending will shift to home and office health, compared to the total $3 billion in revenue that top telemedicine companies generated before the pandemic.

Analysts said to Reuters that a combined Teladoc and Livongo would be the undisputed leader in both online acute care and management of chronic conditions, an area buoyed by President Donald Trump’s executive order on Monday to expand telehealth access to 57 million Americans. Livongo specializes in helping patients manage chronic diseases like diabetes through smart devices and consumer-friendly software.

With the deal, Teladoc said it hopes to create an integrated system through which patients can see a doctor and manage their diseases virtually.

Teladoc will use its shares to pay for most of the deal. Livongo shareholders will receive 0.5920 shares and $11.33 in cash for each of their shares, the companies said in a statement. This will leave Teladoc shareholders with about 58% of the combined company, with Livongo shareholders owning the remainder.

Shares of both companies fell on the news, as investors fretted about Teladoc overpaying and not focusing enough on profitability. This drove down the value of Livongo’s shares, because its shareholders stand to be paid mostly in Teladoc stock.

Teladoc and Livongo shares were down 17% and 10%, respectively, in afternoon trading on Wednesday.

The deal was negotiated almost entirely virtually, according to a source familiar with the discussions.

Read Here

Neha Mule

Neha writes articles on sectors including medicine, food, materials, and science & technology. A qualified statistician, she has the ability to observe and analyze the trends in global markets and write compelling articles that help CXOs in decision making. She is a bookworm and loves to read fiction, lifestyle, science and technology. Neha comes with 6 years of experience in content writing and editing that involves blog writing, preparation of study materials and OERs.

More from Neha Mule

Smart News, Updates and Insights Drive Smarter Decisions

Smart Industry News is a one stop shop of industry news across the globe. We have a team of experts who provides latest updates on industry news to our readers daily. The news available on our website is general information and does not provide our customers with any legal or professional advice specific to any industry...


Subscribe to our newsletter
Get the latest in your inbox weekly Sign up for the fully charged newsletter
Follow Us:
© The News and Media Division of The Insight Partners 2019 | All Rights Reserved